New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial

Oral antitumor therapeutics (OAT) bear a high risk for medication errors, e.g., due to drug–drug or drug–food interactions or incorrect drug intake. Advanced age, organ insufficiencies, and polymedication are putting uro-oncological patients at an even larger risk. This analysis sets out to (1) inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlichtig, Katja, Cuba, Lisa, Dürr, Pauline, Bellut, Laura, Meidenbauer, Norbert, Kunath, Frank, Goebell, Peter J., Mackensen, Andreas, Dörje, Frank, Fromm, Martin F., Wullich, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369799/
https://www.ncbi.nlm.nih.gov/pubmed/35956173
http://dx.doi.org/10.3390/jcm11154558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369799/
https://www.ncbi.nlm.nih.gov/pubmed/35956173
http://dx.doi.org/10.3390/jcm11154558

Ejemplares similares